Well correct me we're it's pumping and it's not correct. AML...

Well correct me we're it's pumping and it's not correct.
AML worth 1 billion which gives us a SP of $6.13
1 bill divided by shares on issue
163 million comes up $6.13
And that's with not giving it a 4x multiple on top.
also, I would like to add historically results have been favourable for AML and 2 patients still alive with their own children that used our drug,
And the FDA have recognised the historical data also.
Now we go to cardio protection an evaluation was given to RAC from an independent evaluatior the triangle report for $5/$8 billion annually in US alone,
now if we go to the low end given that gives us.
$30.67 a share.
Also I did not add the 4x multiple.
Yes we need to get more data for that but it's in process of doing so
And on top of that it's a low evaluation.

and with FTO it's just as big if not bigger.

and you can add another 99 treatments on top that we may be good for.

so tell me we're it's ramping and not true.
Don't try throw me under the bus if you don't understand,
or if I'm not seeing it as you do point out the flaws you see because I don't see any that is concerning at all.